Anemia  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
APPLY-PNH, NCT04558918 / 2019-004665-40: Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Completed
3
97
Europe, Japan, US, RoW
LNP023, iptacopan, Eculizumab, Ravulizumab
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/22
03/23

Download Options